JPRN-UMIN000039021尚未招募未知
Evaluation of intratumoral expression of chemotherapy-associated biomarkers for postoperative adjuvant chemotherarpy against advanced stage lung cancer - Evaluation of expression of chemotherapy-associated biomarkers
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) with rejection from patient 2) inproper for registrtion judged by medical doctor
研究者
相似试验
招募中
不适用
Pilot study on the determination of intratumoral concentrations of kinase inhibitors in patients with advanced solid malignanciesalle vormen van gevorderde, dwz inoperabele of uitgezaaide, solide tumorenAdvanced solid tumorsmetastasized/inoperable cancer10027655NL-OMON36159Vrije Universiteit Medisch Centrum35
进行中（未招募）
1 期
Investigation of the intra-tumoural concentration and activity of sorafenib in cutaneous schwannomas - Sorafenib in NF2eurofibromatosis, type 2 (acoustic neurofibromatosis)MedDRA version: 14.0 Level: LLT Classification code 10029271 Term: Neurofibromatosis, type 2 (acoustic neurofibromatosis) System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-001789-16-GBPlymouth Hospital NHS Trust14
已完成
4 期
Activity of sorafenib in schwannomasCancerISRCTN49989464Plymouth Hospitals NHS Trust (UK)14
进行中（未招募）
1 期
Phase 1b/2 Study of V937 Injected into Tumors in Combination with Intravenous (IV) PembrolizumabAdvanced/metastatic solid tumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2020-001908-42-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc185
进行中（未招募）
1 期
Phase 1b/2 Study of V937 Injected into Tumors in Combination with Intravenous (IV) PembrolizumabEUCTR2020-001908-42-PTMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc185